



Universitätsklinikum Essen
 Institut für Neuropathologie
 Direktorin: Univ.-Prof. Dr. med. K. Keyvani

Sekretariat: (02 01) 723 3325
 Fax: (02 01) 723 5927
 Email: neuropathologie@uk-essen.de

(ADRESSETTE)

Patientenname: _____

Geburtsdatum: _____

w m

Anforderungsschein Molekulare Diagnostik

Eingangs-Nummer (intern)	Patienten-Name/Vorname	Datum
Tumorzellgehalt (intern)	Anmerkungen	Arzt/Ärztin

ERREGERNACHWEIS

- HPV
- Mycobacterien complex

VERSCHIEDENES

- | | | |
|---|--------------------------------------|--|
| <input type="checkbox"/> IGH (Klonalität) | <input type="checkbox"/> 1p/19q FISH | <input type="checkbox"/> MGMT Promotor Methylierung |
| <input type="checkbox"/> TCR (Klonalität) | <input type="checkbox"/> BCOR-ITD | <input type="checkbox"/> Microsatelliteninstabilität (MSI) |

NGSEQUENZIERUNG

- BRCPlus PANEL**
 BRCA1 (2-24), BRCA2 (2-27), CDH1 (1-16), PALB2 (1-13), PTEN (1-9), TP53 (2-11)
- NPP1.0 PANEL**
 ACVR1 (6-8), BRAF (11,15), CDKN2A (1-3), CDKN2B (1,2), CDKN2C (2,3), CIC (5,6,10,11,14,17,19,20), CTNNA1 (3,4,7,8,9), DICER1 (6,10,11,22,23,25,26,27), EGFR (2,7,8,15,18-21), FGFR1 (3,4,7,13,14,15,17), FUBP1 (1-20), H3F3A (2,3,4), H3F3B (2,3,4), HIST1H3B (1), HIST1H3C (1), HIST2H3C (1), IDH1 (3-10), IDH2 (1-10), KBTBD4 (3), MET (2,3,6,8,11,14,19), NFKBIA (1-6), NOTCH1 (3,6,7,8,9,26,34), NRAS (2,3,4), PDGFRA (5,7,12,14,18), PIC3CA (2,3,5,10,16,21), PIK3R1 (10,11,13,14), PTEN (1-9), RB1 (1-26), STK11 (1-9), TERT-Promotor, TP53 (2-11)
- CCP3.2 PANEL**
 BRAF (11,15), EGFR (18-21), ERBB2 (5,6,15,20,23,29), FGFR1 (3-7,10,12-15,17), FGFR2 (6-15,18), FGFR3 (3,6,7,9,10,12,14,16,18), FGFR4 (3, 6, 9,12,13,15,16), HRAS (2-4), IDH1 (4), IDH2 (4), KIT (9,10,11,13,14,17,18), KRAS (2-4), MET (3,8,11,14,19), NRAS (2-4), PDGFRA (12,14,18), PIK3CA (3,5,8,10,16,21), RET (7,10,11,13-16), STK11 (1-9), TERT-Promotor, TP53 (2-11)
- GIST1 PANEL**
 AKT1 (alle), AKT2 (alle), ATM (alle), BRAF (11,15), CRAF (alle), EGFR (18,19,20,21), FGFR1 (4,5,12-15), FGFR3 (7,10,15), HRAS (2-4), KIT (alle), KRAS (2,3,4), MAP2K1 (alle), MAP2K2 (alle), MAPK1 (alle), MAPK3 (alle), MET (3,8,11,14,19), MTOR (47), NF1 (alle), NRAS (2,3,4), PDGFRA (alle), PIK3CA (2,5,8,10, 21), PTEN (alle), RET (10-16), SDHA (alle), SDHB (alle), SDHC (alle), SDHD (alle), TSC1 (alle), TSC2 (alle)

■ NNGML2.1 PANEL

ALK (22-25), BRAF (11,15), CTNNB1 (3), EGFR (18-21), ERBB2 (5,6,8,15,19,20,23,29), FGFR1 (4-7,10,12-15), FGFR2 (Transcript A:6-11,13-15; Transcript B: 8,9,12,18), FGFR3 (3,6,7,9,10,12,14,16,18), FGFR4 (3,6,9,12,13,15,16), HRAS (2-4), IDH1 (4), IDH2 (4), KEAP (2-6), KRAS (2-4), MAP2K1 (2,3), MET (3,8,11,13, 14,16,17,18,19), NRAS (2-4), NTRK1 (13-17), NTRK2 (14-19), NTRK3 (15-20), PIK3CA (10,21), PTEN (1-8), RET (10, 11, 13, 15, 16), ROS1 (34-41), STK11 (1-9), TP53 (2-11)

GENFUSIONSPRODUKT-NACHWEIS

■ ARCTL PANEL

Auf Fusionen untersuchte Gene (*Exone in Klammern*):

AKT1 (3), ALK (2, 4, 6, 10, 16-23, Intron 19), AXL (18-20), BRAF (7-11), CCND1 (1-4), EGFR (8), FGFR1 (2, 8-10, 17), FGFR2 (2, 5, 7, 8-10, 17), FGFR3 (3, 5, 8-10, 17, Intron 17), MET (2, 4-6, 13-17, 21), NRG1 (1-3, 6), NTRK1 (2, 4, 6, 8, 10-13), NTRK2 (5, 7, 9, 11-17), NTRK3 (4, 7, 10, 13-16), PPARG (1-3, 5), RAF1 (4-7, 9-12), RET (2, 4, 6, 8-14), ROS1 (2, 4, 7, 31- 37), THADA (24-30, 36, 37)

■ ARSAR 3 PANEL

Auf Fusionen untersuchte Gene (*Exone in Klammern*):

ALK (19-22), BCOR (6-8,12,14,15), CAMTA1 (3,8,10), CCNB3 (2-6), CIC (19,20), CSF1R (11-13), EPC1 (9-11), EWSR1 (4-13), FOSB (1-3), FOXO1 (1-3), FUS (4-11,14), GLI1 (4-7), HMGA2 (1-5), JAZF1 (2-4), MAML2 (2,3), MEAF6 (4,5), MKL2 (11-13), NCOA2 (11-14), NTRK1 (2, 4, 6, 8, 10-13), NTRK2 (5, 7, 9, 11-17), NTRK3 (4, 7, 10, 12-16), PAX3 (6-8), PDGFB (2,3), PLAG1 (1-4), ROS1 (2, 4, 7, 31-37), SS18 (4-6, 8-11), STAT6 (1-7, 16-19), TAF15 (5-7), TCF12 (4-6), TFE3 (2-6), TFG (4-7), USP6 (1-3), WWTR1 (3,4), YAP1 (1-9), YWHAE (5)

■ KIAA1549-BRAF-GENFUSIONSPRODUKT-NACHWEIS

SEQUENZIERUNG SANGER

- | | | |
|----------------|----------------|------------------|
| ■ BRAF (11,15) | ■ GNAS1 (7,8) | ■ KRAS (2-4) |
| ■ CTNNB1 (3) | ■ HFE (1,4) | ■ NRAS (2-4) |
| ■ EGFR (18-21) | ■ HIST1H3B (1) | ■ PIK3CA (10,21) |
| ■ H3F3A (2) | ■ IDH1 (4) | ■ TERT-Promotor |
| ■ H3F3B (2) | ■ IDH2 (1) | |

IN SITU HYBRIDISIERUNG

- | | | |
|-----------------------------------|------------------------------|---------------------------------|
| ■ ALK Break Apart | ■ EWS Break Apart | ■ NTRK2 Break Apart |
| ■ BRAF Break Apart | ■ FGFR1 Amplifikation | ■ NTRK3 Break Apart |
| ■ BCL2 Break Apart | ■ FGFR2 Amplifikation | ■ PHF1 Break Apart |
| ■ BCL6 Break Apart | ■ FOXO1 Break Apart | ■ PIK3CA Amplifikation |
| ■ BCR-ABL1 Fusion | ■ FUS Break Apart | ■ RB1 Deletion/Amplifikation |
| ■ CDKN2A/B Deletion/Amplifikation | ■ HER2 (ERBB2) Amplifikation | ■ RET Break Apart |
| ■ CIC Break Apart | ■ JAZF1 Break Apart | ■ ROS1 Break Apart |
| ■ MET Amplifikation | ■ MDM2 Amplifikation | ■ SS18 (SYT) <i>Break Apart</i> |
| ■ COL1A1/PDGFRb Fusion | ■ MYC Amplifikation | ■ TFE3 Break Apart |
| ■ CF51R Break Apart | ■ MYC Break Apart | ■ USP6 Break Apart |
| ■ DDIT3 Break Apart | ■ MYCN Amplifikation | ■ VHL Deletion (LOH) |
| ■ MN1 Break Apart | ■ NR4A3 Break Apart | ■ WWTR1 Break Apart |
| ■ EGFR Amplifikation | ■ NTRK1 Break Apart | ■ YWHAE Break Apart |

■ 850K-METHYLIERUNGSANALYSE

■ ANDERE UNTERSUCHUNGEN: